In the absence of biomarkers for ALK1 status, the tumor types selected for escalation studies and phase 2 trials failed to offer much ground for the antitumor activity of dalantercept, even more so when combined with standard-of-care agents that were already suboptimal in terms of efficacy. Here, ACVRL1 is linked to neoplasm.